Pediatric Reference and Optimal Curves for Hemoglobin

Vid Bijelic1,2, Franco Momoli1, Mira Liebman3

  • 1School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

JAMA Network Open
|June 29, 2026
PubMed

Insights

This study developed new hemoglobin reference curves (RCs) and optimal curves (OCs) for children, improving accuracy over traditional methods. These curves offer better clinical context and highlight potential differences with current World Health Organization (WHO) thresholds.

Area of Science:

  • Pediatric Hematology
  • Clinical Biochemistry
  • Biostatistics

Background:

  • Reference intervals (RIs) are crucial for interpreting pediatric laboratory results.
  • Traditional RIs require age and sex partitioning, leading to limited sample sizes and imprecise estimates.
  • Hemoglobin level modeling as a continuous function of age addresses these limitations.

Purpose of the Study:

  • To establish sex-specific hemoglobin reference curves (RCs) for children.
  • To estimate hemoglobin optimal curves (OCs) using health-based criteria.
  • To complement World Health Organization (WHO) hemoglobin thresholds and inform reporting standards.

Main Methods:

  • Cross-sectional study of healthy Canadian children aged 2 weeks to 10 years.
  • Nonparametric quantile regression with restricted cubic splines to estimate RCs and OCs.
  • Development of a web-based platform for visualizing curves and calculating limits.

Main Results:

  • Hemoglobin RCs and OCs were estimated for 4597 and 3426 children, respectively.
  • Optimal curves (OCs) showed sex-specific differences compared to reference curves (RCs), particularly in younger children.
  • World Health Organization (WHO) thresholds were often higher than the lower limits of the OCs, especially in younger age groups.

Conclusions:

  • Modeled hemoglobin RCs overcome limitations of traditional pediatric RIs.
  • Optimal curves (OCs) provide additional clinical context beyond RIs.
  • Findings suggest potential misalignments between new curves and existing WHO thresholds, particularly for younger children.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...